Sprouty (Spry) proteins modulate signal transduction pathways elicited by receptor tyrosine kinases (RTK). Depending on cell type and the particular RTK, Spry proteins exert dual functions: They can either repress RTK-mediated signaling pathways, mainly by interfering with the Ras/Raf/mitogen-activated protein kinase pathway or sustaining RTK signal transduction, for example by sequestering the E3 ubiquitin-ligase c-Cbl and thus preventing ubiquitylation, internalization, and degradation of RTKs. Here, by the inducible expression of murine Spry4 in pancreatic B cells, we have assessed the functional role of Spry proteins in the development of pancreatic islets of Langerhans in normal mice and in the Rip1Tag2 transgenic mouse model of B-cell carcinogenesis. B cell -specific expression of mSpry4 provokes a significant reduction in islet size, an increased number of A cells per islet area, and impaired islet cell type segregation. Functional analysis of islet cell differentiation in cultured PANC-1 cells shows that mSpry4 represses adhesion and migration of differentiating pancreatic endocrine cells, most likely by affecting the subcellular localization of the protein tyrosine phosphatase PTP1B. In contrast, transgenic expression of mSpry4 during B-cell carcinogenesis does not significantly affect tumor outgrowth and progression to tumor malignancy. Rather, tumor cells seem to escape mSpry4 transgene expression. (Mol Cancer Res 2008;6(3):468 -82) 
Introduction
Receptor tyrosine kinases (RTK) activate signal transduction pathways that control a variety of processes in multicellular organisms, such as proliferation, differentiation, migration, and survival. To ensure a physiologically appropriate biological outcome, the precise spatial and temporal regulation of these signaling pathways is crucial. An effective mechanism of modulation is the evolution of negative-feedback loops, that is, the transcriptional induction of negative regulators by the same pathway that will be eventually inhibited. The Sprouty (Spry) proteins represent one such family of negative regulators of RTK signaling (1) (2) (3) .
Spry was identified in Drosophila as a novel antagonist of fibroblast growth factor (FGF) receptor (FGFR; ref. 4 ) and epidermal growth factor receptor signaling pathways (5) . The mammalian genome contains four Spry genes (Spry1-Spry4) encoding proteins of 32 to 34 kDa (6) (7) (8) (9) . Similar to the Spry protein in Drosophila, all four mammalian isoforms were shown to attenuate the activation of the Ras-Raf-p42/44 extracellular-regulated kinase (p42/44 ERK) pathway induced by various growth factors, including FGF, vascular endothelial growth factor, hepatocyte growth factor, platelet-derived growth factor, insulin, nerve growth factor, and glial cell line -derived neurotrophic growth factor (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Surprisingly, in some cases, Spry proteins fail to repress epidermal growth factor signaling; they even potentiate the activation of this pathway, for example, by the sequestration of the E3 ubiquitin ligase c-Cbl and the prevention of RTK ubiquitylation, internalization, and degradation (9, (18) (19) (20) (21) (22) . These data suggest that in vertebrates, Spry proteins are not simply general inhibitors of RTK signaling but rather selective modulators of different RTK pathways (23, 24) . The four mammalian Spry proteins contain a conserved cysteine-rich COOH-terminal domain and variable NH 2 -terminal domains and interact with a variety of signaling molecules, including c-Cbl, CIN85, Grb2, c-Raf, Frs2, TESK, caveolin-1, and Gap1 (1-3). Other proteins have been implicated in interacting with Spry proteins [e.g., Src or proteintyrosine phosphatase-1B (PTP1B)], but these have not been conclusively shown (25) (26) (27) . Hence, multiple mechanisms exist by which Spry proteins interfere with RTK signaling, depending on the cellular context, the identity of the RTK, or the Spry isoform.
In adult tissues, Spry1, Spry2, and Spry4 are widely expressed (6) (7) (8) , whereas Spry3 expression is restricted to brain and testis (8) . However, the regulation of Spry expression and the functional consequences of Spry activity in adult tissues have not been extensively characterized. During development and organogenesis, the expression pattern of Spry strongly overlaps with known sites of RTK signaling. For example, in the developing zebrafish, Spry4 expression is dependent on FGF8 and FGF3 signaling and antagonizes pathways activated by FGFR1 (28) . In mammals, embryonic tissues, such as brain, heart, gut, lung, and muscle, show a close spatial and temporal interdependence between FGF signaling and Spry gene expression (8, 29) . Loss-of-function analyses in mice confirm the importance of Spry expression for normal development of several organs. Spry1 is an essential antagonist of glial cell line -derived neurotrophic growth factor signaling during kidney induction by regulating morphogenesis of the ureteric epithelium (12) . Spry2 is a negative regulator of glial cell linederived neurotrophic growth factor in the development of enteric nerve cells (11) and it regulates FGF-dependent cell fate transformation in the auditory epithelium, and, when ablated, results in hearing loss (13) . Moreover, Spry2 and Spry4 are responsible for restricting FGF-mediated cross talk between the epithelium and mesenchyme during tooth development (30) . Likewise, ectopic expression of Spry proteins strongly affects the development of different organs. In chicken, constitutive expression of Spry2 and Spry4 results in the repression of FGFmediated limb development (8) and forced expression of Spry2 or Spry4 in epithelial cells of the murine fetal lung severely affects lung growth and branching morphogenesis (31, 32) . Finally, Spry2 interferes with testis development by inhibiting FGF-driven mesonephric cell migration (33) .
Here, we have investigated the functional effect of murine Spry4 (mSpry4) on the development of the endocrine pancreas. Development of the pancreas initiates in the anterior midgut region of the endoderm epithelium. As development proceeds, endocrine precursor cells delaminate from the pancreatic epithelium, migrate into the surrounding mesenchyme, and aggregate into islets of Langerhans-a process requiring cell migration, sorting, and aggregation (34, 35) . However, it is not until several weeks after birth that the pancreas fully matures and islets of Langerhans are established with their distinctive cellular architecture: Non-h cells (a, g, and PP cells expressing glucagon, somatostatin, and pancreatic polypeptide) are localized in the periphery of islets of Langerhans, whereas h cells reside in the center. Studies of pancreas development in mice and rats revealed an important function for FGF signaling in the development of the pancreas (36) (37) (38) (39) (40) (41) (42) . In adult mice, FGFR1 and FGFR2 together with their ligands FGF1, FGF2, FGF4, FGF5, FGF7, and FGF10 are exclusively expressed in h cells of the endocrine pancreas, indicating that FGF signaling may also have a role in differentiated h cells. Indeed, expression of a dominant-negative version of FGFR1 in h cells affects the organization of endocrine cells within the islets of Langerhans, reduces the number of h cells, and impairs glucose homeostasis (39) . Here, we show that the expression of mouse Spry4 in h cells during islet development impairs islet architecture and the sorting of a and h cells.
Because initiation and progression of most, if not all, cancer types are associated with a dysregulation of RTK signaling pathways, Spry proteins may exert critical roles in tumorigenesis via their modulatory functions. Indeed, the expression of Spry1 and Spry2 has been found down-regulated in a variety of cancer types, including cancers of the breast, prostate, and liver and in melanoma cell lines (3, (43) (44) (45) (46) . In addition, melanomas harboring activating mutations of B-Raf are resistant to growth inhibition by Spry2 because the mutated form of Raf no longer binds to Spry2 (46) . However, the functional implications of Spry expression on tumor growth has remained elusive. Hence, in a second set of experiments, we have explored the role of Spry proteins during tumorigenesis by the inducible expression of mSpry4 in a transgenic mouse model of pancreatic h-cell carcinogenesis (Rip1Tag2). In this mouse model, the expression of the SV40 large T antigen in pancreatic h cells leads to the development of h-cell carcinoma through multiple stages, including early hyperplasia, angiogenic hyperplasia, adenoma, and, finally, carcinoma (47) (48) (49) (50) . These experiments reveal that mSpry4 does not significantly affect T antigen -mediated h-cell carcinogenesis, implicating molecular changes that help to overcome Spry-specific, growth-repressive functions on tumor cells.
Results

Pancreatic Endocrine a Cells Express mSpry4
To determine if endogenous mSpry proteins were expressed by cells of the murine pancreas, we stained sections from pancreata of adult C57Bl/6 mice for all four mSpry isoforms with the corresponding anti-mSpry antisera. No expression was detectable for mSpry1, mSpry2, and mSpry3 by any cell type of the mouse pancreas (data not shown). In contrast, endogenous mSpry4 was found expressed in a subset of cells in the islets of Langerhans (Fig. 1A and B) . The localization of these mSpry4-positive cells in the outer rim of the islet was reminiscent of the localization of a cells. Immunofluorescence costaining using antibodies against glucagon as markers for a cells and antimSpry4 sera confirmed that endogenous mSpry4 was exclusively expressed in a cells of the islets of Langerhans (Fig. 1C-E ).
Transgenic Expression of mSpry4 in b Cells Perturbs Islet Organization
Because several members of the FGF family of growth factors and their receptors are expressed in pancreatic h cells, we assessed the effect of h cell -specific mSpry4 expression on islet development. To this end, doxycycline-inducible (tetO) 7 mSpry4 transgenic mice (32) were crossed with transgenic mice in which the rat insulin promoter (Rip1) controls synthesis of the reverse doxycycline transactivator (Rip1rtTA; ref. 51). Ectopic mSpry4 protein was readily detected in h cells of adult double-transgenic Rip1rtTA; (tetO) 7 mSpry4 mice treated with doxycycline for 2 weeks ( Fig. 2A) . In single transgenic littermates, endogenous mSpry4 expression is only found in a cells but not in h cells as also shown above for nontransgenic C57Bl/6 mice ( Fig. 1 and data not shown). In the absence of doxycycline, double-transgenic Rip1rtTA;(tetO) 7 mSpry4 mice exhibited a weak expression of mSpry4 in h cells, indicating low activity of the doxycyclineinducible promoter even in the absence of doxycycline (Fig. 2B) .
Development of the endocrine pancreas starts with pancreatic precursor cells of the duct epithelium invading the surrounding mesenchyme (52, 53) . At around E17.5, the first immature islets are found with ongoing segregation of endocrine cells (i.e., h cells in the center and non-h cells in the periphery; refs. 54, 55) . To induce mSpry4 expression in developing h cells of the embryos, pregnant females were treated from the day of conception with doxycycline. Because the insulin promoter driving reverse tetracycline transactivator in Rip7rtTA mice is active with the first appearance of insulinproducing endocrine cells (E9-10), mSpry4 is thus expressed early during islet development. Costainings for mSpry4 and for the h-cell marker insulin by immunofluorescence revealed the inducibility of the transgene in h cells of embryos, for example at E19.5 ( Fig. 2) . Single-transgenic control animals expressed endogenous mSpry4 in a cells surrounding insulin-positive h cells ( Fig. 2C-E) . In pancreata of doxycycline-treated doubletransgenic animals, the number of mSpry4-positive cells was substantially increased (Fig. 2F) , indicating the induction of h cell -specific mSpry4 expression during embryogenesis. However, the area of insulin-positive cells and the levels of insulin expression were decreased in double-transgenic mice ( Fig. 2G ; Table 1 ). In fact, only a small number of h cells coexpressed mSpry4 and insulin, and within these, insulin levels were reduced (Fig. 2H-K) .
To analyze a-and h-cell distribution in the developing pancreas, we costained for insulin and glucagon expression in pancreata of E19.5 double-transgenic Rip1rtTA;(tetO) 7 mSpry4 and single-transgenic mice. In control embryos, a large part of the endocrine pancreas was already organized into normal islets of Langerhans with glucagon-expressing a cells surrounding insulin-positive h cells (Fig. 2L) . Such well-structured islets were not observed in doxycycline-induced Rip1rtTA; (tetO) 7 mSpry4 mice (Fig. 2M) . The average islet size in these embryos was significantly reduced at E19.5 compared with islets of littermate controls; the area of insulin-expressing h cells per islet area was decreased; whereas the number of a cells was increased (Table 1) . These results indicate that h cellspecific expression of mSpry4 during development dramatically changes islet morphology and a-and h-cell contribution.
We wondered whether the observed difference in islet architecture represented a delay in development that is compensated for at later stages of pancreas formation. Therefore, analysis of islet morphology was done in pancreata of older animals; in 2-week-old pups (PN 14) , the process of cell segregation is still ongoing whereas in 4-week-old mice (PN 28), islet formation is complete (54) . mSpry4 expression was induced with doxycycline throughout the embryonic development and postnatal life in Rip1rtTA;(tetO) 7 mSpry4 mice. In agreement with the results of E19.5 pancreata, a significant reduction in islet size in mSpry4-expressing embryos was also observed at the age of 2 weeks (Table 1 ). In contrast, there was no significant difference in islet size between Rip1rtTA;(tetO) 7 mSpry4 and control littermates at the age of 4 weeks. The area of insulinpositive cells and the levels of insulin expression were decreased and the proportion of a cells per islet area was significantly increased at both time points. To determine the influence of mSpry4 on islet cell type segregation, we quantified the number of missorted a cells (i.e., a cells that were localized centrally to the two most peripheral cell layers of the islet). Only a few missorted a cells were found in islets of 2-week-old and, to a lesser extent, of 4-week-old control mice ( Fig. 2N, arrow ; Table 1 ). However, in both age groups analyzed, the number of missorted a cells was significantly higher in mSpry4-expressing Rip1rtTA;(tetO) 7 mSpry4 mice ( Fig. 2O ; Table 1 ). When mice were treated with doxycycline starting only after birth and sacrificed at 4 weeks of age, islet architecture in these mice showed a significant increase in the amount of total a cells and in the number of missorted a cells (data not shown). We found that this phenotype is fully penetrant. Furthermore, glucose tolerance tests revealed that the phenotype in islet architecture caused by mSpry4 expression does not affect glucose metabolism in 5-week-old mice ( Supplementary Fig. S1 ). From these data, we conclude that the presence of mSpry4 in h cells does not result in a major defect of pancreas development but impairs islet cell sorting during all stages of endocrine pancreas development.
mSpry4 Inhibits Migration and Adhesion without Affecting p42/44 ERK Activation
Human pancreatic PANC-1 cells have been used as a useful model to study early stages of pancreatic endocrine islet formation (56, 57) . Grown in normal serum -containing medium, PANC-1 cells form an epithelioid, adherent monolayer. When cultured in defined serum-free medium, the cells begin forming islet-like cell aggregates that differentiate into cells expressing markers of the endocrine pancreas, such as insulin, glucagon, or somatostatin (56) . This process is strongly dependent on FGF signaling, whereby FGF2 expressed by PANC-1 cells serves as a chemoattractant to induce migration and aggregation of these cells into islet-like cell aggregates (56) . Thus, we considered PANC-1 cells a suitable model to assess mSpry4 function during islet formation on a cellular FIGURE 1. mSpry4 expression in pancreata of adult C57Bl/6 mice. Immunohistochemical staining (brown ) of pancreatic sections from an adult C57Bl/6 mouse using anti-mSpry4 antisera (A) or preimmune sera (B). Immunofluorescence staining of a pancreatic section from adult C57Bl/6 mouse for the a-cell marker glucagon (C; red) and for mSpry4 (D; green ). Note that mSpry4 and glucagon are coexpressed in the same cells (E; m e r g e , y e l l o w ) . S c a l e b a r s , 100 Am.
FIGURE 2. Transgenic mSpry4
expression in h cells. Immunohistochemical staining of pancreatic sections from adult Rip1rtTA;(tetO) 7 mSpry4 mice treated with doxycycline for 2 wk (A) or not treated at all (B) using anti-mSpry4 antisera (brown ). Histologic sections of developing pancreas of mouse embryos at E19.5 from single or nontransgenic control littermates (C-E) and double-transgenic Rip1rtTA; (tetO) 7 mSpry4 mice (F-H). Immunofluorescent costaining using antimSpry4 sera (C and F; green) and antibodies against the h-cell marker insulin (D and G; red). Merged pictures (E and H; yellow). I to K. level. For this purpose, PANC-1 cells were infected with adenovirus encoding mSpry4 (AdmSpry4) or luciferase as control (AdLite). Adenovirus-mediated expression of mSpry4 in these cells was confirmed by immunoblot analysis (data not shown).
To assess whether mSpry4 can interfere with cell migration of PANC-1 cells, Transwell migration assays were done. In serum-free medium, PANC-1 cells did not migrate (data not shown). The presence of 10% FCS in the medium induced migration of PANC-1 cells, which was significantly inhibited by the expression of mSpry4 (Fig. 3A) . Inhibitory effects of Spry4 on directed cell movement was assessed by supplementing the medium in the lower Transwell chamber with 10% FCS or with 100 ng/mL FGF2. In accordance with previously published data, where FGF2 in the lower chamber serves as a strong chemoattractant for PANC-1 cells (56), mSpry4 efficiently repressed such serum-and FGF2-induced directional cell migration (Fig. 3A) . However, Spry4-expressing cells, but not controlvirus -infected cells, underwent apoptosis after 4 to 5 days of culture, thus excluding any long-term analysis (data not shown).
Previously, it has been shown that the formation of islet-like cell aggregates is initiated by brief exposure of PANC-1 cells to low concentrations of trypsin followed by incubation in serumfree medium, suggesting that PANC-1 cells cluster together by paracrine chemotaxis via FGF2 (56) . In the presence of mSpry4, the capacity of PANC-1 cells to migrate after brief trypsin exposure was significantly reduced (Fig. 3A) . Cell-cell and cell-matrix adhesion also plays an important role in cell type segregation in organ development (58) and thus may affect the formation of islets of Langerhans. When analyzed for adhesion to uncoated versus collagen IV -coated tissue culture plates, mSpry4 strongly inhibited adhesion of PANC-1 cells to both (Fig. 3B) . Together, these data indicate that mSpry4 is a general inhibitor of PANC-1 adhesion and motility, which does not discriminate between chemokinesis (nondirectional, random movement) and chemotaxis (directional movement).
Next, we assessed whether the inhibitory effects of mSpry4 on migration and adhesion were achieved by attenuation of p42/44 ERK activation. PANC-1 cells were infected with AdmSpry4 or AdLite, starved overnight, and stimulated with various growth factors known to induce p42/44 ERK activation. Notably, mSpry4 had no effect on pp42/44 ERK levels for any of the activated signaling pathways (Fig. 3C ). These data suggest that mSpry4 inhibits adhesion and migration of PANC-1 cells by a mechanism that either acts downstream of p42/44 ERK activation or independently thereof.
mSpry4 Expression Interferes with the Localization of PTP1B
Previously, Spry proteins have been reported as inhibitors of cell migration (25) (26) (27) , with PTP1B, a phosphatase known to be involved in integrin signaling (59, 60) , as a critical mediator of the antimigratory actions of Spry2 (27) . We therefore analyzed PTP1B levels in lysates of PANC-1 cells infected with AdmSpry4 or AdLite. Expression of mSpry4 in these cells led to an increase in the levels of PTP1B in the soluble fraction of cell lysates with a concomitant decrease of PTP1B levels in the cell fraction that is insoluble in Triton X-100 (Fig. 4A) , suggesting that mSpry4 modulates the subcellular localization of PTP1B.
Immunofluorescence stainings of cells grown on uncoated coverslips revealed that PTP1B in AdLite control-infected PANC-1 cells localized in a pattern typical for proteins that were associated with the endoplasmic reticulum ( Fig. 4B ; ref. 61 ). In contrast, in mSpry4-expressing PANC-1 cells, PTP1B was distributed throughout the cytosol (Fig. 4C) . When grown on coverslips coated with collagen IV, control cells showed a concentration of PTP1B at punctate structures in the margins of the cells (Fig. 4D) , identified previously as cell matrix adhesion sites (61) . In contrast, the expression of mSpry4 mostly perturbed the localization of PTP1B (Fig. 4E) . As shown by phalloidin/ actin staining, mSpry4 did not affect the cytoskeletal organization of the cells (Fig. 4F and G) , excluding the possibility that the effect of mSpry4 on PTP1B localization was due to general changes in cytoskeletal architecture.
These results raise the possibility that mSpry4 attenuates migration and adhesion of PANC-1 cells by perturbing the correct localization of PTP1B and thereby interfering with integrin function (25, 26) . Applying the PANC-1 cell system as a model for islet formation, we hypothesize that this inhibitory function of mSpry might play an important role in migration and sorting of endocrine cells during pancreas development, as observed by the expression mSpry4 in vivo.
mSpry4 Expression during Pancreatic b-Cell Carcinogenesis To investigate the functional role of mSpry4 in tumor development, we used Rip1Tag2 mice, a well-characterized transgenic mouse model of pancreatic h-cell carcinogenesis, and determined the role of ectopic expression of mSpry4 in hcell tumor development in Rip1Tag2;Rip1rtTA;(tetO) 7 mSpry4 triple-transgenic mice. Expression of the transgene was induced by doxycycline at different stages of tumorigenesis: (a) from week 5 to 8 (initiation of tumorigenesis); (b) from week 7 to 10 (tumor outgrowth); and (c) from week 10 to 12 (progression from benign to malignant tumors). Littermates negative for either of the transgenes [Rip1rtTA or (tetO) 7 mSpry4 or both] were used as controls.
Inducible mSpry4 expression in islets and tumors was analyzed by immunoblotting analysis of pooled tumor lysates (Fig. 5A ) and by immunohistochemical staining of pancreatic sections using anti-mSpry4 sera ( Fig. 5B-E) . In pancreata of 8-week-old Rip1Tag2 tumor mice, most islets were still comparable in size and morphology with islets of C57Bl/6 mice, with a cells in the islet periphery expressing endogenous mSpry4 (Fig. 5B) . In Rip1Tag2;Rip1rtTA;(tetO) 7 mSpry4 mice, transgenic mSpry4 expression was induced by doxycycline in h cells of small and hyperplastic islets of 8-week-old (Fig. 5C ) and 12-week-old triple-transgenic mice (Fig. 5D) . However, the number of cells expressing the transgene markedly declined in adenomas and carcinomas of 10-and 12-week-old mice, in which large areas of the tumors were negative for mSpry4 expression ( Fig. 5E ; Table 2 ). Costaining for mSpry4 and insulin by immunofluorescence revealed that the expression of the two proteins was not concomitantly lost, indicating that the reduced mSpry4 expression is not due to a loss of insulin promoter activity (data not shown). In addition, upon analysis of ERK phosphorylation in the pooled tumor lysates (Fig. 5A) , the effect of mSpry4 expression on p42/44 ERK activation was variable. In some cases, mSpry4 moderately attenuated ERK activation, reflecting the heterogeneity of mSpry4 expression in these tumors. We therefore conclude that a selection against were seeded on 8-Am pore size Transwell inserts. The medium in the upper and/or lower chambers was supplemented with 10% FCS or 100 ng/mL FGF2 as indicated. Cells treated with trypsin were exposed to low levels of trypsin after 3 h of adhesion to the Transwell membrane and incubated for another 4.5 h in serum-free medium (SFM ) alone or with 100 ng/mL FGF2 in the lower chamber as indicated. Columns, mean; bars, SD; representative of four replicates. The graph is representative of two independent experiments. *, P < 0.05; **, P < 0.01 (Student's t test, two-tailed). B. Adhesion assay. PANC-1 cells infected with AdmSpry4 or with control virus (AdLite) were seeded on collagen IV (Col IV ). After 2.5 h, unattached cells were washed off with PBS. Attached cells were fixed, stained with crystal violet, lysed, and absorbance was measured at A 595 . Columns, mean; bars, SD; representative of four replicates. The graph is representative of two independent experiments. *, P < 0.05; **, P < 0.01 (Student's t test, two-tailed). C. Growth factor stimulation. Cells infected with AdmSpry4 or control virus (AdLite) were starved overnight and then stimulated for 30 min with FGF2, epidermal growth factor (EGF ), platelet-derived growth factor-B (PDGF-B ), hepatocyte growth factor (HGF ), or with medium supplemented with 10% FCS as indicated. Lysates were resolved by SDS-PAGE and resulting immunoblots were sequentially probed with anti-phosphorylated p42/44 ERK and anti-total p42/44 ERK antibodies before visualization and quantification with an Odyssey imager. Levels of phospho-p42/44 ERK were normalized against total p42/44 ERK levels. The immunoblot shown is representative of three independent experiments. To assess whether mSpry4 expression in h cells has any effect on tumor incidence or tumor size, isolated pancreata from 10-and 12-week-old Rip1Tag2;Rip1rtTA;(tetO) 7 mSpry4 mice and from control littermates were analyzed macroscopically. Total numbers of tumors per mouse were not affected by ectopic mSpry4 expression, and a small, and not significant, reduction in tumor volumes was observed in triple-transgenic mice versus control littermates (Table 3) . These results suggest that although mSpry4 is not affecting the onset of tumorigenesis, it has a slight effect on tumor growth. Quantification of tumor cell proliferation by bromodeoxyuridine (BrdUrd) incorporation assays revealed that in all three cohorts, the proliferation rate of cells was slightly decreased in tumors expressing transgenic mSpry4 compared with tumors of control mice (Table 3) . Analysis of tumor cell apoptosis by terminal deoxyribonucleotide transferase -mediated nick-end labeling (TUNEL) assays revealed a significant decrease in apoptosis only in tumors of 8-week-old Rip1Tag2; Rip1rtTA;tetOPmSpry4 mice compared with tumors of control littermates, whereas there was no difference in tumor cell apoptosis in 10-week-old mice and only a slight, yet not significant, increase in 12-week-old mice (Table 3) . Doubleimmunofluorescence staining by TUNEL assay and with antimSpry4 antibodies did not reveal any correlation between mSpry4 expression and apoptosis within individual cells (data not shown), suggesting that mSpry4-expressing cells are not more prone to cell death than cells without mSpry4 expression. To test for the possibility that transgenic mSpry4 expression could repress tumor progression, tumors were staged according to their histology into normal/hyperplastic islets, adenomas, and carcinomas of three grades with increasing malignancy (62) . No differences in tumor progression between Rip1Tag2;Rip1rtTA; (tetO) 7 mSpry4 mice and control littermates were observed at any time point (Table 4) .
Together, the data indicate that expression of mSpry4 in h tumor cells only moderately impairs tumor growth by modestly repressing tumor cell proliferation. However, h tumor cells seem to select against the expression of mSpry4.
No Effect of mSpry4 on Tumorigenicity of Cultured b Tumor Cells
To investigate the effect of mSpry4 on tumor growth at a cellular level, we established several independent h tumor cell lines from tumors of Rip1Tag2;Rip1rtTA;(tetO) 7 mSpry4 mice and control littermates. Inducible high expression of mSpry4 in h tumor cell lines isolated from triple-transgenic animals was confirmed by immunoblotting analysis (Fig. 6A) . In contrast to the moderate repression of proliferation in h tumor cells in vivo (Table 3) , the expression of mSpry4 had no effect on h tumor cell proliferation in vitro (Fig. 6B ).
To test whether mSpry4 could inhibit p42/44 ERK activation in cultured h tumor cells, h tumor cell lines from Rip1Tag2; Rip1rtTA;(tetO) 7 mSpry4 mice were cultured in the presence and absence of doxycycline for 2 days to induce mSpry4 expression and were stimulated with different growth factors under starvation conditions. Immunoblotting analysis of the phosphorylation status of p42/44 ERK revealed that ERK signaling was constitutively activated in all cell lines that could not be further stimulated by any of the growth factors tested (Fig. 6C) . Notably, in contrast to the heterogeneity of mSpry4 activity observed in the pooled tumors (Fig. 5A ), mSpry4 expression in the various tumor cell lines isolated could not attenuate phosphorylation of p42/44 ERK, independent of starvation or stimulation with different growth factors.
Finally, we investigated whether mSpry4 could affect the tumorigenic potential of cultured h tumor cells. Rip1Tag2; Rip1rtTA;(tetO) 7 mSpry4 h tumor cells were injected s.c. into the flanks of immunodeficient nu/nu mice; one cohort of mice was subsequently treated with doxycycline in the drinking water. Inspection of tumor growth over the course of 6 weeks revealed that there was no significant difference in growth of the transplanted tumors in the presence or absence of mSpry4 expression (Table 5) . Taken together, these results show that growth and tumorigenicity of cultured h tumor cells, initially transformed by SV40 T antigen, is not affected by mSpry4 expression.
Discussion
In this study, we have investigated the effect of transgenic mSpry4 expression in h cells in islet development and h-cell tumorigenesis. We show that endogenous mSpry4 is exclusively expressed in a cells of the developing and adult Normal/hyperplastic islets  62  62  34  38  32  35  Adenoma  19  18  21  21  20  20  81  80  55  59  52  55  Carcinoma  G1  15  16  16  16  15  14  G2  3  3  27  22  31  30  G 3  1  1  2  3  2  1  19  20  45  41  48 islets of Langerhans. Inducible expression of transgenic mSpry4 in h cells substantially changes islet morphology. Islets expressing mSpry4 in h cells are smaller in size, contain more a cells per islet area, and exhibit a defect in the sorting of a and h cells to the islet periphery and center, respectively. We tested several ways to explain these alterations caused by the ectotopic expression of mSpry4 in h cells. mSpry4 in h cells may affect signaling pathways underlying cell fate decisions, for example by repressing h-cell and favoring a-cell differentiation. Indeed, the expression of a dominant-negative version of FGFR1 in h cells has resulted in a net loss of insulin-positive cells without increasing h-cell apoptosis (39) . These authors propose an autocrine loop of FGF signaling that might be involved in terminal differentiation and/or maturation of h cells. Our immunofluorescence microscopy analysis of pancreata of Rip1rtTA;(tetO) 7 mSpry4 mice reveals that the mSpry4 transgene and the endogenous insulin gene are rarely coexpressed in the same cell and, if so, that insulin levels in these cells are clearly decreased ( Fig. 2F-K ; Table 1 ). Based on these results, we hypothesize that mSpry4 might interfere with FGF-mediated h cell maturation. However, in the dominant-negative FGFR1 neonates, neither islet organization nor the number of a cells have been affected, indicating that inhibition of FGFR1 signaling is not sufficient to explain the phenotype observed by the inducible expression of mSpry4 in developing h cells of Rip1rtTA;(tetO) 7 mSpry4 embryos and newborn mice. Also, mSpry4 could affect migration and aggregation of endocrine cells during development. Induction of precursor cell migration via FGFRs has been suggested to occur during pancreas development in rats (36, 42) . However, although Spry proteins are mainly known for their repressive functions on the Ras/Raf/p42/44 ERK pathway, our experiments with PANC-1 cells suggest that mSpry4 inhibits cell adhesion and movement A. Inducible mSpry4 expression.
Tumor cell lines isolated from Rip1-Tag2;Rip1rtTA and Rip1Tag2;Rip1-rtTA;(tetO) 7 mSpry4 mice were treated with doxycycline for 2 d.
Lysates were resolved by SDS-PAGE and resulting immunoblots were sequentially probed with antimSpry4 antisera and antibodies against p42/44 ERK as loading control. The immunoblot shown is representative of three independent experiments. B. Cell proliferation.
Tumor cell lines established from tumors of three different Rip1Ta-g2;Rip1rtTA;(tetO) 7 mSpry4 mice and one Rip1Tag2;Rip1rtTA mouse were grown with (continuous line ) or without (dashed line ) doxycycline-induced mSpry4 expression.
C. Growth factor stimulation. Cultured h tumor cells treated with doxycycline for 24 h were starved overnight and then stimulated for 30 min with FGF2, EGF, hepatocyte growth factor (HGF), plateletderived growth factor-B (PDGF-B), or incubated in medium supplemented with 10% FCS as indicated.
Lysates were resolved by SDS-PAGE and the resulting immunoblots were sequentially probed with the antibodies indicated. Levels of phospho-p42/44 ERK were normalized against total p42/44 ERK levels.
by a mechanism that does not affect the p42/44 ERK activation status (Fig. 3) . Previously, it has been reported that Spry proteins are able to affect cell migration by inhibiting the activation of the small GTPase Rac1 (15, 26, 33) . Moreover, mSpry2 expression leads to a relocalization and thereby to an enhanced activation of PTP1B that, in turn, dephosphorylates and inhibits the Rac1 activator p130Cas (27) . In PANC-1 cells, we observed a shift in PTP1B localization from structures resembling the endoplasmic reticulum and focal adhesion sites in the absence of mSpry4 expression to a cytosolic localization in the presence of mSpry4 (Fig. 4) . Despite numerous attempts, we have been unable to show a direct interaction between Spry2 or Spry4 with either the wild-type or a substrate-trapping (D181) form of PTP1B under stimulatory conditions (data not shown). PTP1B is known to repress cell migration and adhesion by interfering with integrin signaling, but conflicting models exist for the exact mechanism of PTP1B function (59, 60, 63) . However, it is interesting to note that mice lacking the b 1 integrin gene specifically in h cells recapitulate the a-/h-cell sorting phenotype observed by the h cell -specific expression of mSpry4 (64) , suggesting that integrin signaling may indeed play a critical role in islet cell segregation. An identical cell sorting phenotype of the endocrine pancreas has also been described in mice lacking the cell adhesion molecule NCAM or in transgenic mice expressing a dominantnegative version of E-cadherin specifically in h cells (54, 65) . Differences in cell adhesion capabilities in two motile cell types can serve as a driving force for segregation and sorting of these cell types, whereby less cohesive cells surround a core of more cohesive cells (58) . Here, we show that mSpry4 inhibits matrix adhesion and migration of cells (Fig. 3A and B) . Hence, the expression of endogenous mSpry4 in a cells might establish a difference in cohesiveness of a versus h cells and thereby affect islet cell segregation and the maintenance of islet organization. In contrast, transgenic expression of mSpry4 in h cells of Rip1rtTA;(tetO) 7 mSpry4 mice compromises such differences in adhesion and migration, resulting in the observed islet cell sorting phenotype.
Both the loss of NCAM (54) and the loss of h 1 integrin function (64) mimic the islet cell sorting phenotype caused by the h cell -specific expression of mSpry4. Previously, we have reported that NCAM binds and activates FGFR in an FGFindependent manner, thereby activating the Ras/Raf/p42/44 ERK pathway, which leads to h 1 integrin -mediated cell adhesion and migration (66) . The inhibition of cell adhesion and migration by mSpry4 reported here is thus consistent with the mSpry4-mediated repression of the FGFR signaling pathway. Yet, our results suggest that mSpry4 may act downstream of p42/44 ERK activation, possibly by modulating the subcellular localization and activity of PTP1B (see above) and/ or by additional mechanisms remaining to be explored. Additionally, it has been reported that homotypic cell-cell contact of h cells influences insulin production, suggesting that the organization of h cells in the core of the islet is crucial for correct islet function (67, 68) . The perturbed a-and h-cell localization, together with the reduced islet size and reduced insulin staining in mice expressing mSpry4 in h cells, does not interfere with blood glucose homeostasis as revealed by glucose tolerance tests (Supplementary Fig. S1 ).
We report here that mSpry4, when expressed in untransformed h cells, causes a significant phenotype in the developing pancreas. On the other hand, in Rip1Tag2 mice, where h cells are transformed by SV40 large T antigen, the effect of transgenic mSpry4 is less pronounced. The presence of mSpry4 leads only to a modest decrease in tumor size (Table 3) , which is most likely due to slightly reduced tumor cell proliferation. This notion, together with the observation that mSpry4 has a heterogeneous effect on ERK activation and that larger tumors seem to negatively select against mSpry4 expression (Fig. 5) , suggests that transformed h cells are not completely refractory to mSpry4 function. However, the effects of mSpry4 on h-cell carcinogenesis in Rip1Tag2 mice are minor and not significant probably due to the inclusion in the analysis of tumors with heterogeneous, low, or no expression of mSpry4. That transformed h cells are refractory to mSpry4 is further confirmed by experiments with h tumor cell lines established from Rip1Ta-g2;Rip1rtTA;(tetO) 7 mSpry4 mice: Their proliferation, their activation of p42/44 ERK by different growth factors, and their tumorigenicity in transplanted mice are not at all affected by mSpry4 ( Fig. 6 ; Table 5 ). Selection against transgene expression during Rip1Tag2 tumorigenesis is not without precedent: h cell -specific expression of a stabilized form of h-catenin also decreased during tumor progression (69) . Transcriptional silencing is the most likely process by which these transgenes are being selected against in large h-cell tumors of Rip1Tag2 mice.
Whereas the modulatory function of Spry proteins on RTKmediated signaling pathways has been extensively studied, their roles in carcinogenesis has only recently begun to be addressed. Gene expression surveys have revealed that Spry1 and Spry2 are down-regulated during the etiology of several cancer types, including cancers of the breast, prostate, and liver and melanoma (3, (43) (44) (45) (46) . Apparently, tumors seek to ablate the antagonistic activities of Spry proteins. However, high levels of expression of Spry2 in melanoma carrying the B-Raf V599E mutation and of Spry1 and Spry4 in gastrointestinal stromal tumors have been reported (3, 70) . Finally, the data shown here suggest that besides selecting against the expression of Spry proteins, tumors can be resistant to the antagonistic function of Spry proteins. Accordingly, a number of transformed cell lines are not affected by the expression of any Spry isoform, regardless of the cancer type and the oncogenic transformation event (71). 5 Understanding the molecular basis of the acquisition of such resistance against Spry function as well as of the selection against Spry expression is certainly a key future task in the further design of therapeutic measures to interfere with RTK-mediated carcinogenesis.
Materials and Methods
Transgenic Mice
Rip1rtTA transgenic mice were generated according to standard procedures and have been described elsewhere (51). The mice express the reverse tetracycline transactivator under the control of the rat insulin promoter (Rip1). Rip1rtTA mice were crossed with transgenic (tetO) 7 mSpry4 mice in which the 5 Our unpublished results.
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expression of murine Spry4 is driven by a promoter consisting of the reverse tetracycline transactivator binding element (tetO) 7 linked to an inactive cytomegalovirus minimal promoter (tetO) 7 mSpry4 (32). Double-transgenic Rip1rtTA; tet(O) 7 mSpry4 mice were crossed with Rip1Tag2 mice to generate the triple-transgenic Rip1Tag2;Rip1rtTA; tet(O) 7 mSpry4 offspring. Generation and phenotypic characterization of Rip1Tag2 mice has been described previously (49) . All mouse lines were strictly kept in a C57Bl/6 background. The PCR primers used for genotyping were as follows: Rip1rtTA, 5 ¶-CATCTCAATGGCTAAGGCGTC-3 ¶ and 5 ¶-GA-CCAGCTACAGTCGGAAACC-3 ¶; (tetO) 7 mSpry4, 5 ¶-CACC-GGGACCGATCCAGC-3 ¶ and 5 ¶-GAAGTGCTGCTACTGC-TGCTTA-3 ¶; and Rip1Tag2, 5 ¶-GGACAAACCACAACTAGA-ATGGCAG-3 ¶ and 5 ¶-CAGAGCAGAATTGTGGAGTGG-3 ¶. All animal experimentations were in accordance with the guidelines of the Swiss Federal Veterinary Office and the regulations of the Cantonal Veterinary Office of Basel-Stadt.
Transgene Induction Experiments
Transgenic mSpry4 expression was induced by addition of doxycycline (1 mg/mL, Sigma Chemical Co.) to the drinking water in light-protected bottles. The water was replaced every second day. To express mSpry4 during embryogenesis, pregnant females were treated with doxycycline. Days of gestation were dated by detection of the vaginal plug. Doubletransgenic Rip1rtTA;tet(O) 7 mSpry4 and single-transgenic control littermates were sacrificed at 2 or 4 wk, respectively. Tripletransgenic tumor mice [Rip1Tag2;Rip1rtTA;tet(O) 7 mSpry4] were treated with doxycycline for 2 to 3 wk before sacrifice at the age of 7, 10, or 12 wk. Tumor incidence was determined macroscopically, and tumor volumes were calculated from the tumor diameter by assuming a spherical shape of the tumors.
Glucose Tolerance Test
Five-week-old double-transgenic Rip1rtTA;tet(O) 7 mSpry4 and single-transgenic control littermates were starved overnight. After 12 h, 2 mg glucose (200 mg/mL diluted in PBS) per gram of body weight was injected into the tail vein. Blood glucose levels were measured every 30 min for 2 h using AccuCheck Sensor (Roche Diagnostics).
b Tumor Cell Injection into Nude Mice
Athymic nude-Fox-N1 nu/nu mice were obtained from Harlan Sprague-Dawley. h Tumor cells (1 Â 10 6 ) positive for both Rip1rtTA and (tetO) 7 mSpry4 transgenes were injected into the flanks of the mice. Mice were treated with doxycycline (1 mg/mL) in their drinking water from the day of injection or left untreated. Mice were sacrificed 6 wk after tumor cell injection.
Histology
Pancreata were fixed overnight at 4jC in 4% paraformaldehyde in PBS (pH 7.4) before processing and embedding in paraffin. Five-micrometer thick sections were cut for immunohistochemical analysis. For BrdUrd labeling, mice were injected i.p. with 100 mg BrdUrd (Sigma) per gram of body weight 2 h before tumor isolation. Rabbit sera against mSpry4 peptides were generated as previously described (71) and used for immunohistochemical and immunofluorescent analysis of mSpry4 expression. The following additional antibodies were used: guinea pig anti-insulin (DakoCytomation), goat antihuman glucagon (Santa Cruz Biotechnology), and biotinylated mouse anti-BrdUrd (Zymed). Antibody specificity was confirmed by incubating pancreatic sections without primary antibody or with preimmune sera.
Apoptotic cells were visualized with the in situ Cell Death Detection kit for peroxidase (Roche). All biotinylated secondary antibodies (Vector) were used at a 1:200 dilution, and positive staining was visualized with the ABC horseradish peroxidase kit and 3-amino-9-ethylcarbazole substrate kit for peroxidase (Vector) according to the manufacturer's instructions. For the analysis of tissue morphology, slides were counterstained with hematoxylin.
For immunofluorescence analysis, Alexa Fluor 568 -and Alexa Fluor 488 -labeled secondary antibodies diluted 1:200 were used (Invitrogen). For nuclear counterstain, 6-diamidino-2-phenylindole (Sigma) was used. For quantitation of proliferation (BrdUrd incorporation) and apoptosis (TUNEL reaction), the numbers of nuclei staining positive for BrdUrd or the TUNEL reaction were determined in 7 to 10 comparable fields per section with a Â40 objective, and the mean of positive cells F SD per field was calculated. Blind analyses of insulin and glucagon double stainings were used to group mice in doxycycline-induced Rip1rtTA;tetOmSpry4 transgenics and control littermates. The areas of mSpry4-and insulin-expressing cells in tumors and islets were quantified by ImageJ software (ImageJ).
Cell Culture
PANC-1 cells were obtained from the American Tissue Culture Collection. For the generation of tumor cell lines, Rip1Tag2 mice carrying one or both of the transgenes Rip1rtTA and tet(O) 7 mSpry4 were sacrificed at the age of 12 wk. Pancreatic tumors were isolated using a dissecting microscope, and tumor cell lines were established as described previously (72) . All cells were maintained at 37jC with 5% CO 2 and cultured in high glucose DMEM, containing 10% fetal bovine serum and 2 mmol/L glutamine. Doxycycline (2 Ag/mL) was added to normal medium to induce mSpry4 expression in tumor cells.
For proliferation assays, cell numbers were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, at t 0 , 1 Â 10 5 h tumor cells were seeded onto 24-well plates. Every 24 h, MTT (Sigma) was added to the cells at 0.5 mg/mL and incubated at 37jC for 90 min. Cells were solubilized in 500 AL of 95% isopropanol, 5% formic acid. Absorption of the solution was determined at 570 nm. For cell migration assays, PANC-1 cells (3 Â 10 4 per well) were seeded onto 8-Am pore size Transwell membranes (BD Biosciences) and incubated with medium without sera or medium supplemented with either 10% FCS or 100 ng/mL FGF2 in the lower or upper chamber as indicated. After 4.5 h, cells on top of the membranes were removed with sterile cotton swabs; membranes were fixed with 4% paraformaldehyde for 15 min at room temperature and stained with crystal violet (0.5% in 20% methanol, Sigma) for 20 min at room temperature. Labeled cells that had migrated through the membrane were counted using a Â20 objective on a Zeiss microscope (Zeiss).
Matrix adhesion assays were done as previously described (66) . Ninety-six -well plates were left uncoated or coated with 5 Ag/cm 2 of mouse collagen IV (BD Biosciences) according to the manufacturer's recommendation, and PANC-1 cells (5 Â 10 4 per well) were seeded and incubated for 2.5 h. Nonadherent cells were removed by washing with PBS. Adherent cells were fixed for 20 min with 25% glutaraldehyde, stained with crystal violet, and solubilized with 10% acetic acid. Absorbance was measured at 595 nm.
Adenoviral constructs encoding the mouse Spry4 cDNA (AdmSpry4) and the firefly luciferase cDNA (AdLite) were generated as described previously (73) . Viral quantities were based on protein content using the conversion of 1 mg viral protein = 3.4 Â 10 12 virus particles. For viral infection of PANC-1 cells, culture medium was replaced with starvation medium (DMEM, 2 mmol/L glutamine) containing 2,500 virus particles per cell. After 5 h, the medium was replaced with fresh growth medium for another 5 h before overnight starvation and stimulation with growth factors the following day. PANC-1 and h tumor cells were stimulated for 30 min by the addition of recombinant human FGF2 (50 ng/mL), epidermal growth factor (50 ng/mL), hepatocyte growth factor (20 ng/mL), or plateletderived growth factor (30 ng/mL; Catalys AG/Promega or Sigma).
Immunoblotting
PANC-1 and h tumor cells were lysed for 30 min on ice in lysis buffer [1% Triton X-100, 160 mmol/L NaCl, 20 mmol/L Tris (pH 8.0), 2 mmol/L Na 3 VO 4 , 10 mmol/L NaF and a 1:200 dilution of stock protease inhibitor cocktail for mammalian cells (Sigma)]. Tumor tissue samples were pooled and lysed in tissue lysis buffer [0.5% Triton X-100, 100 mmol/L NaCl, 2.5 mmol/L EDTA, and 10 mmol/L Tris (pH 8.0)]. Protein concentration was determined using a modified Bradford protocol (Bio-Rad Protein Assay; Bio-Rad Laboratories). Equal amounts of protein were dissolved in SDS-PAGE loading buffer and resolved by 12% SDS-PAGE. SDS-PAGE gels were transferred to polyvinylidene fluoride (Millipore) by semidry transfer in Towbin's buffer (20% methanol, 25 mmol/L Tris, 192 mmol/L glycine), blocked with either 4% bovine serum albumin or 5% skim milk powder in TBS with 0.05% Tween 20 (TBST). Primary and secondary antibodies were diluted in 4% bovine serum albumin or 5% skim milk powder in TBST. The following primary antibodies were used: mouse monoclonal anti-phosphorylated p42/44 ERK (Sigma), rabbit polyclonal anti-p42/44 ERK (Sigma), goat polyclonal anti-actin (Santa Cruz Biotechnology), and mouse monoclonal anti-PTP1B (BD Biosciences). Expression of mSpry4 was analyzed using rabbit sera against mSpry4 peptide as previously described (71) . The following secondary antibodies conjugated to horseradish peroxidase were used: goat anti-mouse IgG (Sigma or Jackson Immunoresearch), rabbit anti-goat IgG (Sigma), and donkey anti-rabbit IgG (Amersham or Jackson Immunoresearch). Detected antibodies were visualized using enhanced chemiluminescence (GE Health Sciences/Amersham Biosciences or Interchim). In some cases, immunoblots were also visualized and quantitated using an Odyssey Imager (Li-Cor Biotechnology). In these cases, the following secondary antibody conjugates were used: goat anti-mouse Alexa 680 (Invitrogen) and goat anti-rabbit IRDye 800 (Rockland Immunochemicals).
Immunofluorescence
PANC-1 cells were plated on uncoated coverslips or on coverslips coated with 5 Ag/cm 2 of mouse collagen IV (BD Bioscience). After 24 h, cells were fixed using 4% paraformaldehyde for 15 min at 37jC. Cells were permeabilized with cold 0.1% Triton X-100 in PBS for 10 min at 4jC. Then, cells were blocked in 4% goat serum in PBS for 1 h at room temperature. Anti-PTP1B antibody (BD Biosciences) was diluted 1:100 in 4% goat serum and incubated overnight at 4jC. Alexa 488 -conjugated anti-mouse IgG and Alexa 568 -conjugated antiphalloidin antibodies (Molecular Probes) were diluted 1:200 in 4% goat serum. Nuclei were stained with 1 Ag/mL 6-diamidino-2-phenylindole (Sigma) for 10 min at room temperature.
Statistical Analysis
Statistical analyses were done using GraphPad Prism software (GraphPad Software, Inc.).
